プロモーションスケジュール Rezolute, Inc.
詳細なスケジュール
簡易グラフ
会社について Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. さらに詳しく| IPO date | 2014-05-01 |
|---|---|
| ISIN | US76200L3096 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.rezolutebio.com |
| Цена ао | 3.74 |
| 1日あたりの価格変動: | -3.74% (3.74) |
|---|---|
| 週ごとの価格変動: | -6.49% (3.85) |
| 月ごとの料金変更: | -25.93% (4.86) |
| 3ヶ月間の価格変動: | -21.57% (4.59) |
| 半年間の価格変動: | -30.1% (5.15) |
| 年間の価格変動: | +102.25% (1.78) |
| 3年間の価格推移: | +32.84% (2.71) |
| 5年間の価格推移: | +2 516.28% (0.1376) |
| 10年間の価格推移: | 0% (3.6) |
| 年初からの価格変動: | -18% (4.39) |
|
|
過小評価
|
効率
|
|||||||||||||||||||||||||||||||||||||
配当金
|
義務
|
成長の衝動
|
|||||||||||||||||||||||||||||||||||||
| 機関 | 音量 | 共有, % |
|---|---|---|
| Federated Hermes, Inc. | 10154327 | 0 |
| Vivo Capital, LLC | 3242842 | 38.52 |
| Nantahala Capital Management, LLC | 3075414 | 36.53 |
| Stonepine Capital Management, LLC | 2768656 | 32.89 |
| First Manhattan Company | 2680978 | 31.85 |
| Blackstone Inc | 1537684 | 18.27 |
| Vanguard Group Inc | 1407652 | 16.72 |
| Caxton Corporation | 1318967 | 15.67 |
| Sphera Funds Management Ltd. | 996710 | 11.84 |
| Adage Capital Partners GP L.L.C. | 631690 | 7.5 |
| ETF | 共有, % | 年間の利益率, % | 配当金, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.05811 | 17.09 | 1.54048 |
| Avantis U.S Small Cap Equity ETF | 0.01284 | 27.77 | 1.68271 |
| Dimensional U.S. Targeted Value ETF | 0.00052 | 26.01 | 1.93487 |
| Dimensional U.S. Core Equity 2 ETF | 0.0002 | 30.76 | 1.47098 |
| 0.02 | 25.41 | 1.66 |
| スーパーバイザー | 役職 | 支払い | 生年 |
|---|---|---|---|
| Mr. Nevan Charles Elam J.D. | Founder, CEO & Acting Chairman of the Board | 973.65k | 1967 (58 年) |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer | 738.86k | 1975 (50 年) |
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific & Patient Affairs | N/A | |
| Mr. Michael R. Deperro | Senior VP & Head of Corporate Development | N/A | |
| Mr. Michael Covarrubias | Senior VP & Head of Program & Portfolio Management | N/A | |
| Mr. Chris Milks | VP & Head of Finance | N/A | |
| Dr. Raj Agrawal M.D. | VP & Head of Ophthalmological Clinical Development | N/A | |
| Ms. Robyn Sweinhart | VP & Head of Quality | N/A | |
| Mr. Daron G. Evans M.B.A., M.S. | Chief Financial Officer | N/A | 1974 (51 年) |
| Ms. Erin O'Boyle | Senior VP & Head of Clinical Operations |
住所: United States, Redwood City. CA, 201 Redwood Shores Parkway - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.rezolutebio.com
Webサイト: https://www.rezolutebio.com
